AbbVie’s Rinvoq (upadacitinib) Receives the CHMP’s Recommendation for Approval to Treat Active Non-Radiographic Axial Spondyloarth...
June 27, 2022
AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval as the First Specific Interleukin-23 to Treat Moderately to Se...
June 20, 2022
AbbVie Presents Five-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia at...
June 10, 2022
AbbVie Published Results of Rinvoq (upadacitinib) & Skyrizi (risankizumab) in Multiple P-III Induction and Maintenance Studies for...
May 27, 2022
AbbVie Signs an Exclusive Worldwide License Option Agreement with Cugene for CUG252 to Treat Autoimmune Diseases
May 17, 2022
AbbVie Reports Results of Rinvoq (upadacitinib) P-III (U-ENDURE) Maintenance Study for the Treatment of Crohn's Disease
May 12, 2022
No more records!
Incisive News in 3 Shots.
First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2022 PharmaShots - All Rights Reserved.